CompletedNot Applicable

Premature Coronary Artery Disease and Familial Dyslipidemia in Patients Presenting With Acute Coronary Syndrome

Egypt2,000 participantsStarted 2021-12-01

Plain-language summary

This study aimed to explore the relationship between familial hypercholesterolemia and premature coronary artery disease, particularly in the context of acute coronary syndrome, by reviewing current evidence and highlighting the need for improved screening and aggressive lipid-lowering strategies in high-risk populations.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years at the time of presentation. * Both sexes. * Confirmed diagnosis of coronary artery disease (CAD), established by clinical presentation, electrocardiographic findings, elevated cardiac biomarkers, and/or angiographic evidence of ≥50% luminal stenosis in at least one major coronary artery. * Hospital admission to the participating cardiology department between \[insert study period, e.g., January 2020 and December 2024\] for acute coronary syndrome (ACS), including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI). * Availability of complete clinical, laboratory, and echocardiographic data necessary for classification and analysis. Exclusion Criteria: * Incomplete medical records or missing essential laboratory, imaging, or demographic data. * Secondary causes of dyslipidemia, including uncontrolled hypothyroidism, nephrotic syndrome, chronic liver disease, or use of lipid-altering medications (other than statins) before presentation. * Previous congenital or structural heart disease, cardiomyopathy, or significant valvular heart disease unrelated to CAD. * Severe chronic kidney disease (estimated glomerular filtration rate \<30 mL/min/1.73 m²) or patients on dialysis. * Autoimmune, inflammatory, or systemic diseases known to influence vascular inflammation or lipid metabolism. * Malignancy or life expectancy \<6 months due to non-cardiac causes. * Pregnant or lactating women. …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Dyslipidemia pattern in patients with acute coronary syndrome

Timeframe: Within 24 hours of hospital admission

Incidence of familial dyslipidemia among patients with acute coronary syndrome

Timeframe: Within 24 hours of hospital admission

Trial details

NCT IDNCT07267312

SponsorCairo University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-27

View on ClinicalTrials.gov More Premature trials